Alto Neuroscience, Inc.

Alto Neuroscience maintains a robust liquidity position with $263.8 million in cash and equivalents against total liabilities of $32.9 million, resulting in a current ratio of 20.52. The balance sheet is lightly leveraged, with a debt-to-equity ratio of 0.07, comprising $13.9 million in long-term debt and $2.1 million in short-term debt. Despite strong liquidity, the company generated negative operating cash flow of $27.1 million in Q1 2026, driven by ongoing operational losses. The market capitalization stands at $922.0 million, implying a price-to-book ratio of 3.79.

The company is not yet profitable, reporting a net loss of $26.2 million and an operating loss of $27.1 million for the quarter. Return on equity is -10.78% and return on assets is -9.5%, reflecting the pre-revenue, high-burn nature of its clinical development stage. The negative EV/EBITDA of -24.85 underscores the absence of earnings. These metrics are consistent with early-stage biopharma firms that prioritize R&D investment over immediate profitability.

Revenue generation is not yet established from commercial sales, as the company relies on financing activities to fund operations. The primary pipeline asset, ALTO-101, is an investigational transdermal PDE4 inhibitor for Cognitive Impairment Associated with Schizophrenia (CIAS). Additionally, data presented in early 2026 highlighted potential benefits of ALTO-203 for indications involving excessive daytime sleepiness and sustained attention impairments. Geographic and segment revenue concentration is not applicable due to the lack of commercial revenue streams.

Growth trajectory is defined by capital raising rather than organic revenue expansion. In Q1 2026, the company raised $120.0 million through a private placement of common stock and pre-funded warrants, offset by $4.9 million in related payments. This contrasts with the prior year period where financing activities were driven by term loan issuances and repayments. The net increase in cash of $87.3 million in Q1 2026 significantly bolsters the runway for clinical trials.

Risk assessment indicates low liquidity risk due to substantial cash reserves, but medium dilution risk is flagged due to recent equity offerings and the reliance on equity financings since inception. Key flags in source documents mention dilution or offering risk. The company has incurred significant operating losses since inception, necessitating continuous capital raises. The conversion of the K2 term loan into shares of common stock further illustrates the mechanism of debt-to-equity conversion that may impact share count.

Recent events include an 8-K filing with material items under Item 2.02, indicating significant corporate developments. Analyst sentiment is positive, with a mean recommendation of 1.50 (strong buy) and a mean price target of $34.80, suggesting upside from the current market price of $28.03. The company completed its IPO in February 2024, raising $133.0 million in net proceeds, which established its public market presence.

Operating income -$27.1M.

• ▍Operating income -$27.1M

Operating income -$49.3M.

• ▍Operating income -$49.3M

Operating income -$34.4M.

• ▍Operating income -$34.4M

Operating income -$66.4M.

• ▍Operating income -$66.4M

Operating income -$68.6M.

• ▍Operating income -$68.6M

Operating income -$68.6M.

• ▍Operating income -$68.6M

Operating income -$37.8M.

• ▍Operating income -$37.8M